Abstract
The interaction between a low-dose cholinesterase inhibitor, pyridostigmine (PYR), and atropine was investigated by spectral analysis of heart rate fluctuations in eight healthy humans. Each subject was given increasing boluses of IV atropine during treatment with PYR (30 mg·3/day) or placebo. PYR attenuated the bimodal dose-dependent changes in the respiratory peak (which represents the parasympathetic control) in response to atropine. We suggest that spectral analysis can be used for quantifying the complex dose-dependent cholinergic agonist-antagonist interactions, and may help to disclose an asymptomatic low-dose intoxication with acetylcholinesterase inhibitors.
| Original language | English |
|---|---|
| Pages (from-to) | 613-617 |
| Number of pages | 5 |
| Journal | Pharmacology Biochemistry and Behavior |
| Volume | 39 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jul 1991 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Anticholinesterase
- Atropine
- Humans
- Pyridostigmine
- Spectral analysis of heart rate
Fingerprint
Dive into the research topics of 'Modulation of the dose-dependent effects of atropine by low-dose pyridostigmine: Quantification by spectral analysis of heart rate fluctuations in healthy human beings'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver